095700.KQ
Genexine, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 3,260.00
+15.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.0B | 4.6B | 2.9B | 4.4B | 16.1B |
| Cost of Revenue | 8.1B | 8.9B | 4.2B | 4.1B | 8.8B |
| Gross Profit | (3.1B) | (4.3B) | (1.2B) | 302.0M | 7.3B |
| Operating Expenses | |||||
| R&D Expense | 26.7B | 24.1B | 22.0B | 26.3B | 26.4B |
| SG&A Expense | 5.0B | 3.9B | 5.4B | 7.2B | 15.9B |
| General & Admin Expense | 1.6B | 1.8B | 1.8B | 1.9B | 2.5B |
| Selling & Marketing Expense | 1.5B | 2.1B | 3.6B | 5.3B | 2.2B |
| Other Expenses | 4.3B | 3.8B | 8.6B | 4.4B | (1.4B) |
| Total Operating Expenses | 36.0B | 31.7B | 36.0B | 37.9B | 41.0B |
| Cost and Expenses | 44.1B | 40.7B | 40.2B | 45.7B | 49.8B |
| Operating Income (EBIT) | (39.1B) | (36.1B) | (37.2B) | (41.9B) | (31.1B) |
| Non-Operating | |||||
| Interest Income | 986.5M | 904.0M | 1.1B | 1.3B | 243.4M |
| Interest Expense | 5.4B | 2.4B | 2.6B | 4.1B | 3.8B |
| Net Interest Income | (4.4B) | (1.5B) | (1.6B) | (2.8B) | (3.6B) |
| Other Non-Op Income/Expense | 6.8B | 8.9B | (28.2B) | (8.8B) | (23.2B) |
| Non-Operating Income (excl Interest) | (32.0B) | (11.3B) | 25.5B | 4.0B | 2.6B |
| EBT (Pre-Tax Income) | (32.3B) | (27.2B) | (35.8B) | (50.0B) | (56.8B) |
| Income Tax Expense | — | — | (1.7B) | 16.8B | (857.2M) |
| Bottom Line | |||||
| Net Income | (32.1B) | (27.0B) | (63.7B) | (66.9B) | (56.0B) |
| Earnings from Cont. Ops | (32.1B) | (27.0B) | (34.1B) | (66.9B) | (56.8B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.1B) | (27.0B) | (63.7B) | (66.9B) | (56.0B) |
| Per Share | |||||
| Basic EPS | (₩706) | (₩594) | (₩1,511) | (₩1,652) | (₩1,319) |
| Diluted EPS | (₩706) | (₩594) | (₩1,511) | (₩1,652) | (₩1,319) |
| Revenue Per Share | ₩109 | ₩101 | ₩70 | ₩109 | ₩380 |
| Shares | |||||
| Basic Shares Outstanding | 45.5M | 45.5M | 42.2M | 40.5M | 42.4M |
| Diluted Shares Outstanding | 45.5M | 45.5M | 42.2M | 40.5M | 42.4M |
| Profitability Metrics | |||||
| EBITDA | 466.0M | (29.0B) | (57.3B) | (40.9B) | (28.8B) |
| D&A | 6.8B | 7.0B | 5.4B | 5.0B | 4.9B |
| EBIT | (6.3B) | (36.1B) | (62.8B) | (45.9B) | (33.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026